These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 38224955)

  • 1. Improved heart function and cardiac remodelling following sacubitril/valsartan in acute coronary syndrome with HF.
    Liu H; Su Y; Shen J; Jiao Y; Li Y; Liu B; Hou X; Jin Q; Chen Y; Sun Z; Xi Q; Feng B; Fu Z
    ESC Heart Fail; 2024 Apr; 11(2):937-949. PubMed ID: 38224955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI).
    Chen C; Wu X; Li Y; Peng Y
    Ann Palliat Med; 2021 May; 10(5):5455-5461. PubMed ID: 34044572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of sacubitril/valsartan on cardiac function in heart failure rabbits with preserved ejection fraction].
    Gao SY; Yao DH; Li JF; Xie QM; Jiang SC
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):887-893. PubMed ID: 31744278
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of early administration of sacubitril/valsartan after coronary artery revascularization in patients with acute myocardial infarction complicated by moderate-to-severe mitral regurgitation: a randomized controlled trial.
    Yin H; Ma L; Zhou Y; Tang X; Li R; Zhou Y; Shi J; Zhang J
    Heart Vessels; 2024 Aug; 39(8):673-686. PubMed ID: 38635062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.
    Januzzi JL; Prescott MF; Butler J; Felker GM; Maisel AS; McCague K; Camacho A; Piña IL; Rocha RA; Shah AM; Williamson KM; Solomon SD;
    JAMA; 2019 Sep; 322(11):1085-1095. PubMed ID: 31475295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Value of Sacubitril/Valsartan in Acute Anterior Wall ST-Segment Elevation Myocardial Infarction before Emergency Percutaneous Coronary Intervention.
    Lin G; Chen W; Wu M; Dai C; Xu K
    Cardiology; 2022; 147(5-6):479-485. PubMed ID: 36198259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction.
    Murphy SP; Prescott MF; Maisel AS; Butler J; Piña IL; Felker GM; Ward JH; Williamson KM; Camacho A; Kandanelly RR; Solomon SD; Januzzi JL
    Circ Heart Fail; 2021 Jun; 14(6):e008410. PubMed ID: 33998243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan.
    Ibrahim NE; Piña IL; Camacho A; Bapat D; Felker GM; Maisel AS; Butler J; Prescott MF; Abbas CA; Solomon SD; Januzzi JL;
    Circ Heart Fail; 2020 Nov; 13(11):e007829. PubMed ID: 33016100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of NT-proBNP in Patients With Successful PCI for ACS and Normal Left Ventricular Ejection Fraction.
    Wang JL; Guo CY; Li HW; Zhao XQ; Zhao SM
    Am J Med Sci; 2022 Apr; 363(4):333-341. PubMed ID: 34986361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients.
    Oh JH; Lee JM; Lee HJ; Hwang J; Lee CH; Cho YK; Park HS; Yoon HJ; Chung JW; Kim H; Nam CW; Han S; Hur SH; Youn JC; Kim IC
    ESC Heart Fail; 2022 Aug; 9(4):2435-2444. PubMed ID: 35484930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
    Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J
    JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
    Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
    JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
    Chen F; Tian G; Bai X; Li J; Yuan Z
    Ann Palliat Med; 2021 Aug; 10(8):8684-8691. PubMed ID: 34488357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of NT-proBNP, 3D LA volume and LV dyssynchrony in patients with acute STEMI undergoing primary percutaneous intervention.
    Siva Sankara C; Rajasekhar D; Vanajakshamma V; Praveen Kumar BS; Vamsidhar A
    Indian Heart J; 2015; 67(4):318-27. PubMed ID: 26304563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Compound Danshen Dripping Pills on Ventricular Remodeling and Cardiac Function after Acute Anterior Wall ST-Segment Elevation Myocardial Infarction (CODE-AAMI): Protocol for a Randomized Placebo-Controlled Trial.
    Wu YJ; Deng B; Wang SB; Qiao R; Zhang XW; Lu Y; Wang L; Gu SZ; Zhang YQ; Li KQ; Yu ZL; Wu LX; Zhao SB; Zhou SL; Yang Y; Wang LS
    Chin J Integr Med; 2023 Dec; 29(12):1059-1065. PubMed ID: 37656413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction.
    Docherty KF; Campbell RT; Brooksbank KJM; Dreisbach JG; Forsyth P; Godeseth RL; Hopkins T; Jackson AM; Lee MMY; McConnachie A; Roditi G; Squire IB; Stanley B; Welsh P; Jhund PS; Petrie MC; McMurray JJV
    Circulation; 2021 Jul; 144(3):199-209. PubMed ID: 33983794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of left ventricular remodeling after ST-elevation myocardial infarction.
    Hendriks T; Hartman MHT; Vlaar PJJ; Prakken NHJ; van der Ende YMY; Lexis CPH; van Veldhuisen DJ; van der Horst ICC; Lipsic E; Nijveldt R; van der Harst P
    Int J Cardiovasc Imaging; 2017 Sep; 33(9):1415-1423. PubMed ID: 28389968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of sacubitril-valsartan on left ventricular remodeling and NT-proBNP in patients with heart failure complicated with hypertension and reduced ejection fraction.
    Xie B; Gao Q; Wang Y; Du J; He Y
    Am J Transl Res; 2024; 16(5):1935-1944. PubMed ID: 38883372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status.
    Murphy SP; Ward JH; Piña IL; Felker GM; Butler J; Maisel AS; Meng X; Prescott MF; Solomon SD; Januzzi JL
    JACC Heart Fail; 2022 Dec; 10(12):976-988. PubMed ID: 36456072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.